Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study.

Woolf RT, West SL, Arenas-Hernandez M, Hare N, Peters van Ton AM, Lewis CM, Marinaki AM, Barker JN, Smith CH.

Br J Dermatol. 2012 Jul;167(1):165-73. doi: 10.1111/j.1365-2133.2012.10881.x.

PMID:
22309614
2.

A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.

Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J.

J Eur Acad Dermatol Venereol. 2008 Jan;22(1):19-24. Epub 2007 Nov 19.

PMID:
18031504
3.

HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis.

Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, Richerson R.

Clin Chem. 2003 Oct;49(10):1632-41.

4.

Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.

Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC.

Arthritis Res Ther. 2015 Oct 22;17:295. doi: 10.1186/s13075-015-0814-z.

5.

The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.

Chládek J, Simková M, Vanecková J, Hroch M, Chládkova J, Martínková J, Vávrová J, Beránek M.

Eur J Clin Pharmacol. 2008 Apr;64(4):347-55. Epub 2007 Dec 29.

PMID:
18163165
7.

A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.

Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, Mader RM.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):156-63. Epub 2012 Apr 13.

PMID:
22152098
8.

A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.

Panetta JC, Yanishevski Y, Pui CH, Sandlund JT, Rubnitz J, Rivera GK, Ribeiro R, Evans WE, Relling MV.

Cancer Chemother Pharmacol. 2002 Nov;50(5):419-28. Epub 2002 Sep 24.

PMID:
12439601
9.

Understanding the variation in response to methotrexate.

Becher G, Burden AD.

Br J Dermatol. 2012 Jul;167(1):2-3. doi: 10.1111/j.1365-2133.2012.11028.x. No abstract available.

PMID:
22738410
10.

The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children.

Rahman SI, Siegfried E, Flanagan KH, Armbrecht ES.

J Am Acad Dermatol. 2014 Feb;70(2):252-6. doi: 10.1016/j.jaad.2013.10.001. Epub 2013 Dec 9.

PMID:
24332314
11.
12.

Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.

Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, Smith K, Caldwell J, Furst DE.

Pharmacogenetics. 2004 Nov;14(11):733-9.

PMID:
15564880
13.

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.

Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.

PMID:
21910713
14.

Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.

Saurat JH, Langley RG, Reich K, Unnebrink K, Sasso EH, Kampman W.

Br J Dermatol. 2011 Aug;165(2):399-406. doi: 10.1111/j.1365-2133.2011.10399.x. Epub 2011 Jul 11.

PMID:
21564071
15.

Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.

Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, Barclay ML.

Arthritis Rheum. 2010 Feb;62(2):359-68. doi: 10.1002/art.27201.

16.

Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis.

den Boer E, de Rotte MC, Pluijm SM, Heil SG, Hazes JM, de Jonge R.

J Rheumatol. 2014 Nov;41(11):2167-78. doi: 10.3899/jrheum.131290. Epub 2014 Sep 15.

PMID:
25225283
17.

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM.

N Engl J Med. 2011 Oct 27;365(17):1586-96. doi: 10.1056/NEJMoa1010858.

19.

Determination of erythrocyte methotrexate polyglutamates by liquid chromatography/tandem mass spectrometry after low-dose methotrexate therapy in Chinese patients with rheumatoid arthritis.

Mo X, Wen Y, Ren B, Chen J, Xu C, Wang X, Huang M, Chen X.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:41-8. doi: 10.1016/j.jchromb.2012.08.032. Epub 2012 Sep 1.

PMID:
22999476
20.

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE.

J Clin Invest. 1996 Jan 1;97(1):73-80.

Supplemental Content

Support Center